DP
NVO

Dearborn Partners’s Novo Nordisk NVO Stock Holding History

Dearborn Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,972
Closed -$342K – 270
2024
Q4 		$342K Buy
3,972
+400
+11% +$43.3K 0.01% 201
2024
Q3 		$425K Hold
3,572
– – 0.02% 190
2024
Q2 		$510K Buy
3,572
+200
+6% +$26.5K 0.02% 166
2024
Q1 		$433K Hold
3,372
– – 0.02% 177
2023
Q4 		$349K Buy
3,372
+500
+17% +$49.4K 0.01% 189
2023
Q3 		$261K Hold
2,872
– – 0.01% 204
2023
Q2 		$232K Hold
2,872
– – 0.01% 216
2023
Q1 		$229K Buy
+2,872
New +$204K 0.01% 221
2022
Q3 		– Sell
-3,596
Closed -$200K – 263
2022
Q2 		$200K Buy
+3,596
New +$200K 0.01% 249

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Dearborn Partners's NVO Position: Q1 2025 in Review

Dearborn Partners sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 3,972 shares — an estimated $342K sold.

Dearborn Partners first reported a position in NVO in Q2 2022 and held it in 9 quarters. The position peaked at $510K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Dearborn Partners reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Dearborn Partners sold 3,972 Novo Nordisk shares in Q1 2025, an estimated $342K.
  • Dearborn Partners first reported a position in Novo Nordisk in Q2 2022 and held it in 9 quarters.
  • Dearborn Partners's Novo Nordisk position peaked at $510K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Dearborn Partners's 13F filing for Q1 2025, filed 8 May 2025.